Loreclezole
Based on 1 Customer Validation
Loreclezole, an antiepileptic compound, is a selective GABAA receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 117857-45-1
- Formula: C10H6Cl3N3
- Molecular Weight:274.53
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B0009
Flumazenil
-
HY-100369A
DMCM hydrochloride
-
HY-B0007
Baclofen
-
HY-103531
CGP52432
-
HY-100991
FG 7142
-
HY-10233
Gaboxadol hydrochloride
-
HY-105272R
Loreclezole (Standard)
-
HY-17354
(R)-Baclofen
-
HY-103520
DS2
-
HY-19567
PK 11195
-
HY-107994
Aminooxyacetic acid hemihydrochloride
-
HY-B0799
Dihydroergotoxine mesylate
Biological Activity
GABAA receptor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male Lister Hooded rats[3].
-
Dosage:10, 25, 50 or 75 mg/kg.
-
Administration:IP, 60 min before measurement of seizure threshold.
-
Result:Resulted in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later.
Chemical Information
-
CAS No. 117857-45-1
-
Appearance Solid
-
Molecular Weight 274.53
-
Formula C10H6Cl3N3
-
Color White to off-white
-
SMILES
Cl/C(C1=C(C=C(Cl)C=C1)Cl)=C\N2C=NC=N2
-
Synonyms
R 72063
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 110 mg/mL (400.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 3.12 mg/mL (11.36 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wingrove PB, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4569-73. [Content Brief]
[2]. Sanna E, et al. Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60. [Content Brief]
[3]. Green AR, et al. A behavioural and neurochemical study in rats of the pharmacology of loreclezole, a novel allosteric modulator of the GABAA receptor. Neuropharmacology. 1996;35(9-10):1243-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6426 mL | 18.2129 mL | 36.4259 mL | 91.0647 mL |
| 5 mM | 0.7285 mL | 3.6426 mL | 7.2852 mL | 18.2129 mL | |
| 10 mM | 0.3643 mL | 1.8213 mL | 3.6426 mL | 9.1065 mL | |
| 15 mM | 0.2428 mL | 1.2142 mL | 2.4284 mL | 6.0710 mL | |
| 20 mM | 0.1821 mL | 0.9106 mL | 1.8213 mL | 4.5532 mL | |
| 25 mM | 0.1457 mL | 0.7285 mL | 1.4570 mL | 3.6426 mL | |
| 30 mM | 0.1214 mL | 0.6071 mL | 1.2142 mL | 3.0355 mL | |
| 40 mM | 0.0911 mL | 0.4553 mL | 0.9106 mL | 2.2766 mL | |
| 50 mM | 0.0729 mL | 0.3643 mL | 0.7285 mL | 1.8213 mL | |
| 60 mM | 0.0607 mL | 0.3035 mL | 0.6071 mL | 1.5177 mL | |
| 80 mM | 0.0455 mL | 0.2277 mL | 0.4553 mL | 1.1383 mL | |
| 100 mM | 0.0364 mL | 0.1821 mL | 0.3643 mL | 0.9106 mL |
Loreclezole Related Classifications
HY-105272 Related Classifications
Powered by Bioz